Saturday 17 October 2026
Export CGTX’s income statement to Excel — free account
Cognition Therapeutics, Inc.
CGTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.6% and free cash flow grew 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.73
0.00
0.00%
Follow CGTX
Cognition Therapeutics, Inc. (CGTX) P/E ratio
Cognition Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.8× (November 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.8×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CSBR Champions Oncology, Inc. compare | n/m |
| HYFT MindWalk Holdings Corp. compare | n/m |
| HRTX Heron Therapeutics, Inc. compare | n/m |
| NMAD Nomad Power Solutions, Inc. compare | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| PDSB PDS Biotechnology Corporation compare | n/m |
| CGTX Cognition Therapeutics, Inc. | n/m |
| MNOV MediciNova, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)